University of Edinburgh Featured PhD Programmes
University of Exeter Featured PhD Programmes
University of Warwick Featured PhD Programmes
University College London Featured PhD Programmes
FindA University Ltd Featured PhD Programmes
10 miles

Queen’s University Belfast Cancer / Oncology PhD Projects, Programs & Scholarships

We have 10 Queen’s University Belfast Cancer / Oncology PhD Projects, Programs & Scholarships

  • Cancer / Oncology×
  • Queen’s University Belfast×
  • clear all
Order by 
Showing 1 to 10 of 10
  Queen's University Belfast-NCI Cancer Research Four-Year Doctoral Training Programme

Funding Type

PhD Type

KEY PROGRAMME INFORMATION. ENTRY YEAR. 2020. PROGRAMME LENGTH*. 4 year(s). * In year 1, you will complete a Masters Programme at Queen's University Belfast, followed by a three-year PhD programme based at the US National Cancer Institute (NCI) in Washington DC, USA.
  Developing and Analysing models for cancer invasion
  Dr A Zhigun
Application Deadline: 30 November 2019

Funding Type

PhD Type

Cancer cell migration is an essential stage in the development and expansion of tumours and their metastases. Once a malignant tumour arises in some part of the body, it can grow and make its way through the surrounding tissue matrix in order to reach the blood vessels.
  Dissecting novel mechanisms of cysteine protease biology in tumourigenesis
  Dr R Burden, Prof C Scott
Applications accepted all year round

Funding Type

PhD Type

Proteases are known for their role in facilitating tumour development, primarily through processes such as proliferation and invasion.
  Long-acting drug delivery from intravaginal rings for treatment of cervical intraepithelial neoplasia
  Prof K Malcolm, Dr P Boyd
Applications accepted all year round

Funding Type

PhD Type

Building on our world-renowned expertise in vaginal drug delivery, the aim of this project is to develop a long-acting vaginal ring device for treatment of cervical intraepithelial neoplasia.
  Nano-engineered Delivery Systems for the Targeted Delivery of Oncology Drugs for Non-Small Cell Lung Cancer
  Dr H McCarthy, Dr N Buckley
Applications accepted all year round

Funding Type

PhD Type

Lung cancer is the most common cancer worldwide accounting for 11.6% of the global burden. The standard of care (SoC) chemotherapy typically involves a ‘cocktail’ of drugs which confer debilitating side-effects, resulting in sub-optimal dosing with a reduced clinical efficacy.
  Peptide hydrogels as novel nanotherapeutic delivery agents enhancing the anti-tumour efficacy of radiotherapy
  Dr J Coulter, Dr G Laverty
Applications accepted all year round

Funding Type

PhD Type

There is a pressing clinical need for effective localised cancer treatments. Addressing this need we will develop a novel drug delivery system comprised of a nanoparticle/drug releasing hydrogel implant.
  Personalised Medicine for Breast and Ovarian Cancer
  Dr N Buckley, Dr H McCarthy
Applications accepted all year round

Funding Type

PhD Type

One in two people will develop cancer in their lifetime and it is a leading cause of death. While significant progress has been made in the treatment of some cancers, there still remain some forms of the disease with limited treatment options and poor outcome.
  SMART Nanocarriers for Cancer
  Dr W Al-Jamal
Application Deadline: 15 November 2019

Funding Type

PhD Type

An important limitation in the treatment of cancer with chemotherapeutics is the inability to achieve therapeutically effective local drug concentrations avoiding healthy tissue damage.
  To develop an allosteric inhibitor of HDAC6 inhibition in cancer
  Dr F Furlong, Dr I Tikhonova
Applications accepted all year round

Funding Type

PhD Type

The HDAC6 protein is upregulated in cancer and associated with increased proliferation and metastasis. Several HDAC6 inhibitors have been developed and are in clinical trials.
  USP17 as a cancer therapeutic target
  Dr J Burrows
Applications accepted all year round

Funding Type

PhD Type

USP17 is over-expressed in a range of primary tumours including NSCLC, breast, colorectal, cervical, ovarian and osteosarcoma and its depletion has been shown to block the growth of cells from all these cancer types.
Show 10 15 30 per page
  • 1


FindAPhD. Copyright 2005-2019
All rights reserved.